Antibody-mediated enhancement of viral disease

Current Topics in Microbiology and Immunology

Volumn 260, Issue , 2001, Pages 145-169

  Sullivan, N J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; VIRUS ANTIBODY;

ANTIBODY DEPENDENT ENHANCEMENT; CELL SPECIFICITY; CLINICAL FEATURE; DENGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TARGET CELL; VACCINE PRODUCTION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034972091     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-662-05783-4_8     Document Type: Review

References (81)

1. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1
2. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
3. A model in mice for the study of the early death phenomenon after vaccination and challenge with rabies virus
4. Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV
5. Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion
6. Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?
7. Complement receptor mediates enhanced flavivirus replication in macrophages
8. + T-cell counts and T-cell function in long-term AIDS-free infection
9. Antibody dependent plaque enhancement by monoclonal antibodies against Japanese encephalitis virus
10. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects
11. Mechanisms of opsonized HIV entry in normal B lymphocytes
12. Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of ross river virus infection
13. Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis
14. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection
15. Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection
16. Replication of dengue viruses in cultures of peripheral blood leukocytes from dengue-immune rhesus monkeys
17. Effect of immune status on dengue 2 virus replication in cultured leukocytes from infants and children
18. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
19. Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials
20. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
21. Enhancement of human immunodeficiency virus (HIV) replication in human monocytes by low titres of anti-HIV antibodies in vitro
22. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans
23. Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals
24. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors
25. Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques
26. Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes
27. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
28. Antibody-dependent enhancement of infection and the pathogenesis of viral disease
29. Disease severity-related antigenic differences in dengue 2 strains detected by dengue 4 monoclonal antibodies
30. Profiles of antibody-dependent enhancement of dengue virus type 2 infection
31. Study of the distribution of antibody-dependent enhancement determinants on dengue 2 isolates using dengue 2-derived monoclonal antibodies
32. Dengue and chikungunya virus infection in man in Thailand, 1962-1964. I. Observations on hospitalized patients with hemorrhagic fever
33. Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody
34. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages
35. The differentiation state of monocytic cells affects their susceptibility to infection and the effects of infection by dengue virus
36. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
37. Antibodies in human infectious disease
38. Antibody-dependent enhancement of plaque formation on cell lines of macrophage origin - A sensitive assay for antiviral antibody
39. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines
40. Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies
41. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1
42. Acute rabies death mediated by antibody
43. Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1
44. Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection
45. Mapping of the interaction between the immunodominant loop of the ectodomain of HIV-1 gp41 and human complement protein Clq
46. Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937
47. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS
48. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120
49. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization
50. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro
51. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release
52. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection
53. Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors
54. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees
55. The Emperor's New Clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever
56. Immunopathogenesis of dengue hemorrhagic fever
57. Antibody response in dengue and dengue hemorrhagic fever
58. An insular outbreak of dengue hemorrhagic fever. II. Virologic and serologic studies
59. Risk factors in dengue shock syndrome: A prospective epidemiologic study in Rayong. Thailand. I. The 1980 outbreak
60. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
61. Antibody-mediated infection of macrophages and macrophage-like cell lines with 17D-yellow fever virus
62. Effect of complement consumption by cobra venom factor on the the course of primary infection with simian immunodeficiency virus in rhesus monkeys
63. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1
64. Modulation of primary human immunodeficiency virus type 1 envelope glycoprotein-mediated entry by human antibodies
65. Retrospective study of Western blot profiles in immune sera of natural dengue virus infections
66. Rabies vaccines: Duration-of-immunity study in dogs
67. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1
68. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies
69. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates
70. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization
71. In vitro analysis of complement-dependent HIV-1 cell infection using a model system
72. Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120
73. Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection: CD4 and Fcγ R
74. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry
75. Further characterization of the interaction between the Clq subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1
76. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity
77. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein
78. Human immunodeficiency virus infection in two cohorts of homosexual men: Neutralising sera and association of anti-gag antibody with prognosis
79. Recurrence of epidemic dengue hemorrhagic fever in an insular setting
80. An insular outbreak of dengue hemorrhagic fever. I. Epidemiologic observations
81. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5